N-Myc a key gene promoting a worst prostate cancer progression

Prostate cancer is a lethal disease and despite several treatments available prognosis of patients with metastatic castration resistant prostate cancer (mCRPC) still remain poor.

Natural clinical history of the disease generally involves a phase of hormone-sensitive prostate cancer followed by the inexorable acquisition of resistance to androgen deprivation therapy. MCRPC is a clinical disease associated to resistance to androgen deprivation and other treatment approaches are required for its management. These mainly include: chemotherapy and new hormonal agents able to exercise a more effective hormone-production inhibition.

Despite these approaches, after variable time, prostate cancer cells develop resistance to systemic.

The clinical history of prostate cancer is strictly associated to a large time-heterogeneity in terms of genomic profile of tumour cells. Systemic treatment exercise, an external pressure which progressively leads to cancer cells evolution and acquisition of novel genomic alterations.

One of the most impressive changes could be observed in a transition of prostate cancer cells in a neuroendocrine phenotype, which is associated to poor clinical outcomes.

Berger et al. have carried out a further characterization of molecular models employed by cancer cells to escape from these external pressures in a recent study (1).

Briefly they proposed a mechanism by which N-Myc overexpression may leads to important epigenetic and transcriptomic reprogramming leading to acquisition of castration resistant status and evolution to neuroendocrine prostate cancer. Of interest, the identification of this alteration in addition to a specific molecular signature could help clinicians to early identify tumours more likely to evolve to NEPC (1). This would leads to development of personalized strategies in terms of clinical monitoring in course of therapy and early inclusion of these patients in clinical trials at time of progression.

Molecular mechanisms related to androgen and hormone inhibition resistance is a key and still not well-understood issue in prostate cancer (2,3).

There are several mechanisms proposed as primary driver of hormone resistance.

One of the most assessed mechanisms consisted on the production of slice variants of the androgen receptor (AR) (4,5). Normally AD is a ligand-dependent receptor able to promote gene transcription after dihydrotestosterone or testosterone binding. Alternative splicing of AR may lead to the development to different molecular structures of this receptors. Sometime these alternative structures may be directly active promoting transcription of target genes regardless the presence of natural ligand. As known AR-V7, AR-V12 are the most assessed splice variants associated to constitutional activity and hormone-inhibition resistance (4,5).

The presence of restored AR signalling due to AR-activating mutations, AR active splice variants, intra-tumoral production of androgen compounds are also mechanisms by which prostate cancer cells may acquire resistance to systemic hormonal treatments (4,5).

Epigenetic modifications are another mechanism proposed to overcome hormonal inhibition. Several genes showed an altered methylation compared to normal prostate tissue including: SCGB3A1, HIF3A, AOX1, P115, ALKBH5, ATP11A, FHAD1, KLHL8, FLNC, EFS, ECRG4, PITX2, PDLIM4 and KCMA1 (6-8). Altered methylation strictly depends by altered activity of specific enzymes that belong to the family of DNA-methyltransferase. Also, modification of histones is involved in development of castration resistant status. Indeed, modifications of histone molecular conformations significantly modify accessibility of chromatin to transcription (6-8). The enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase enzyme of the Polycomb Repressive Coplex 2 (PRC2) which is strictly related to repression of several genes able to inhibit cell proliferation including p53. There is a known supposed association between EZH2 hyper-expression and development of more aggressive tumour phenotype (9-12).

In the already cited article of Berger et al. there was a confirmation of previously observations which suggested a strictly interaction between N-Myx and EZH2. In absence of EZH2 cells up-regulated genes, which were down-regulated by N-Myc (1).

EZH2 inhibitors are under investigation in combination with abiraterone and enzalutamide (NCT03480646) or with AR antagonist (NCT03741712) as there are strong evidences supporting a restored androgen response mediated by EZH2 inactivation.

Other promising strategies to overcome hormonal resistance are under investigation (13).

These involve: the adoption of histone deacetylase inhibitors, the use of PI3K-AKT-mTOR inhibitors, cyclins inhibitors and BET inhibitors (14,15).

Of these inhibitors of the bromodomain and extra terminal (BET) family proteins and bromodomain-containing proteins are of particular interest. Indeed these proteins are able to modulate the recruitment of other proteins modifying DNA transcription. Further evidences show that different BRD are able to interact with AR in the nucleus and mediate AR target genes transcription (14,15).

PI3K-AKT-mTOR pathway is strictly related to AR. Indeed through down-regulation of PHLPP in course of AR inhibition the PI3K pathway could be restored. Furthermore, loss of PTEN is associated to PI3K-AKT-mTOR pathway promotion and to development of CRPC (16,17). Thus, the association of inhibitor of PI3K-mTOR is a promising approach in the management of advanced MCRPC and several trials are ongoing (NCT03072238, NCT02121639).

In conclusion studies able to reveal novel insights about molecular altered pathways in prostate cancer are a critical issue. The novel evidences which correlate N-Myc to the development of more aggressive prostate tumors and in particular to cancer with neuroendocrine phenotype is of particular interest.

The attractive possibility to early identify tumours more likely to progress, as neuroendocrine subtypes should be further investigated. In particular, the more and more early administration of new hormonal compounds as well as the possibility to include these patients in clinical trials should justify the development of translational studies aimed to further investigate this issue (18).

Another issue that should be assessed is the alteration of N-Myc in a particular clinical setting composed of patients with metastatic hormone sensitive prostate cancer (mHSPC), which are known to be associated to worst clinical outcomes despite an increasing availability of active and effective systemic treatments.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This was an invited article commissioned and reviewed by the Section Editor Dr. Xiao Li, MD (Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China).

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.12.63). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Berger A, Brady NJ, Bareja R, et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest 2019;130:3924-40. [Crossref] [PubMed]
2. Mollica V, Di Nunno V, Cimadamore A, et al. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells 2019; [Crossref] [PubMed]
3. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015;15:701-11. [Crossref] [PubMed]
4. Paschalis A, Sharp A, Welti JC, et al. Alternative splicing in prostate cancer. Nat Rev Clin Oncol 2018;15:663-75. [Crossref]
5. Sharp A, Coleman I, Yuan W, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest 2019;129:192-208. [Crossref] [PubMed]
6. Geybels MS, Zhao S, Wong CJ, et al. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue. Prostate 2015;75:1941-50. [Crossref] [PubMed]
7. Zhao S, Geybels MS, Leonardson A, et al. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clin Cancer Res 2017;23:311-9. [Crossref] [PubMed]
8. Vanaja DK, Ehrich M, Van den Boom D, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 2009;27:549-60. [Crossref] [PubMed]
9. Labbé DP, Sweeney CJ, Brown M, et al. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res 2017;23:7072-83. [Crossref] [PubMed]
10. Cimadamore A, Gasparrini S, Santoni M, et al. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev Mol Diagn 2018;18:645-55. [Crossref] [PubMed]
11. Wang HJ, Pochampalli M, Wang LY, et al. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene 2019;38:17-32. [Crossref] [PubMed]
12. Karanikolas BD, Figueiredo ML, Wu L. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res 2009;7:1456-65. [Crossref] [PubMed]
13. Ciccarese C, Massari F, Iacovelli R, et al. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treat Rev 2017;54:68-73. [Crossref] [PubMed]
14. Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol 2017;28:1776-87. [Crossref] [PubMed]
15. Asangani IA, Dommeti VL, Wang X, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014;510:278-82. [Crossref] [PubMed]
16. Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 2015;67:795-802. [Crossref] [PubMed]
17. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86. [Crossref] [PubMed]
18. Di Nunno V, Mollica V, Santoni M, et al. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. Clin Genitourin Cancer 2019;17:e871-7. [Crossref] [PubMed]